Deutsche Bank Aktiengesellschaft Upgrades Sanofi (NASDAQ:SNY) to “Hold”

Sanofi (NASDAQ:SNY) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Marketbeat.com reports.

Separately, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Sanofi has an average rating of “Moderate Buy” and a consensus target price of $60.00.

Sanofi Stock Performance

Shares of Sanofi stock opened at $54.34 on Thursday. The firm has a market cap of $137.91 billion, a PE ratio of 27.72, a price-to-earnings-growth ratio of 1.21 and a beta of 0.57. The firm’s 50-day simple moving average is $49.24 and its 200-day simple moving average is $52.27. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. Equities analysts forecast that Sanofi will post 3.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sanofi

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Synergy Asset Management LLC purchased a new position in shares of Sanofi in the 4th quarter worth about $25,000. McClarren Financial Advisors Inc. increased its stake in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares in the last quarter. Northwest Investment Counselors LLC purchased a new stake in shares of Sanofi during the third quarter valued at $29,000. Concord Wealth Partners grew its position in Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after purchasing an additional 363 shares during the period. Finally, Fortitude Family Office LLC boosted its holdings in shares of Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after buying an additional 659 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.